|
1
|
Nishio J, Ideta S, Iwasaki H and Naito M:
Scapular osteochondrolipoma: Imaging features with pathological
correlation. Oncol Lett. 6:817–820. 2013.PubMed/NCBI
|
|
2
|
Hillner BE, Siegel BA, Shields AF, et al:
Relationship between cancer type and impact of PET and PET/CT on
intended management: findings of the national oncologic PET
registry. J Nucl Med. 49:1928–1935. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dimitrakopoulou-Strauss A, Strauss LG,
Heichel T, et al: The role of quantitative (18)F-FDG PET studies
for the differentiation of malignant and benign bone lesions. J
Nucl Med. 43:510–518. 2002.PubMed/NCBI
|
|
4
|
Griffeth LK, Dehdashti F, McGuire AH, et
al: PET evaluation of soft-tissue masses with fluorine-18
fluoro-2-deoxy-D-glucose. Radiology. 182:185–194. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Aoki J, Watanabe H, Shinozaki T, et al:
FDG-PET for preoperative differential diagnosis between benign and
malignant soft tissue masses. Skeletal Radiol. 32:133–138. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Charest M, Hickeson M, Lisbona R, et al:
FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a
retrospective review of 212 cases. Eur J Nucl Med Mol Imaging.
36:1944–1951. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tian R, Su M, Tian Y, et al: Dual-time
point PET/CT with F-18 FDG for the differentiation of malignant and
benign bone lesions. Skeletal Radiol. 38:451–458. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Benz MR, Czernin J, Tap WD, et al:
FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses
after Neoadjuvant Therapy in Adult Primary Bone Sarcomas. Sarcoma.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fuglø HM, Jørgensen SM, Loft A, Hovgaard D
and Petersen MM: The diagnostic and prognostic value of
18F-FDG PET/CT in the initial assessment of high-grade
bone and soft tissue sarcoma. A retrospective study of 89 patients.
Eur J Nucl Med Mol Imaging. 39:1416–1424. 2012. View Article : Google Scholar
|
|
10
|
Shin DS, Shon OJ, Byun SJ, et al:
Differentiation between malignant and benign pathologic fractures
with F-18-fluoro-2-deoxy-D-glucose positronemission
tomography/computed tomography. Skeletal Radiol. 37:415–421. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Piperkova E, Mikhaeil M, Mousavi A, et al:
Impact of PET and CT in PET/CT studies for staging and evaluating
treatment response in bone and soft tissue sarcomas. Clin Nucl Med.
34:146–150. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Iagaru A, Quon A, McDougall IR and Gambhir
SS: F-18 FDG PET/CT evaluation of osseous and soft tissue sarcomas.
Clin Nucl Med. 31:754–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Strobel K, Exner UE, Stumpe KD, et al: The
additional value of CT images interpretation the differential
diagnosis of benign vs. malignant primary bone lesions with
18F-FDG-PET/CT. Eur J Nucl Med Mol Imaging. 35:2000–2008. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shin DS, Shon OJ, Hans DS, Choi JH, Chun
KA and Cho IH: The clinical efficacy of (18)F-FDG-PET/CT in benign
and malignant musculoskeletal tumors. Ann Nucl Med. 22:603–609.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eary JF, O’Sullivan F, Powitan Y, et al:
Sarcoma tumor FDG uptake measured by PET and patient outcome: a
retrospective analysis. Eur J Nucl Med Mol Imaging. 29:1149–1154.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Boellaard R, O’Doherty MJ, Weber WA, et
al: FDG PET and PET/CT: EANM procedure guidelines for tumour PET
imaging: version 1.0. Eur J Nucl Med Mol Imaging. 37:181–200. 2010.
View Article : Google Scholar
|
|
17
|
Brenner W, Bohuslavizki KH and Eary JF:
PET imaging of osteosarcoma. J Nucl Med. 44:930–942.
2003.PubMed/NCBI
|
|
18
|
Gurney J, Swensen AR and Bulterys M:
Malignant bone tumors. National Cancer Institute SEER Pediatric
Monograph. ICCC VIII. National Cancer Institute; Bethesda, USA: pp.
99–110. 1999
|
|
19
|
Glasser DB, Lane JM, Huvos AG, Marcove RC
and Rosen G: Survival, prognosis, and therapeutic response in
osteogenic sarcoma: The Memorial Hospital experience. Cancer.
69:698–708. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bacci G, Ferrari S, Bertoni F, et al:
Long-term outcome for patients with nonmetastatic osteosarcoma of
the extremity treated at the istituto orthopedic rizzoli according
to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an
updated report. J Clin Oncol. 18:4016–4027. 2000.PubMed/NCBI
|
|
21
|
Cistaro A, Lopci E, Gastaldo L, et al: The
role of 18F-FDG PET/CT in the metabolic characterization of lung
nodules in pediatric patients with bone sarcoma. Pediatr Blood
Cancer. 59:1206–1210. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fletcher JW, Djulbegovic B, Soares HP, et
al: Recommendations on the use of 18F-FDG PET in oncology. J Nucl
Med. 49:480–508. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Erdi YE: The use of PET for radiotherapy.
Curr Med Imaging Rev. 3:3–16. 2007.
|
|
24
|
de Geus-Oei LF, van der Heijden HF,
Corstens FH and Oyen WJ: Predictive and prognostic value of FDG-PET
in nonsmall-cell lung cancer: a systematic review. Cancer.
110:1654–1664. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lan XL, Zhang YX, Wu ZJ, et al: The value
of dual time point (18)F-FDG PET imaging for the differentiation
between malignant and benign lesions. Clin Radiol. 63:756–764.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xiu Y, Bhutani C, Dhurairaj T, et al:
Dual-time point FDG PET imaging in the evaluation of pulmonary
nodules with minimally increased metabolic activity. Clin Nucl Med.
32:101–105. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sahlmann CO, Siefker U, Lehmann K and
Meller J: Dual time point 2-[18F]fluoro-2′-deoxyglucose positron
emission tomography in chronic bacterial osteomyelitis. Nucl Med
Commun. 25:819–823. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Johnson GR, Zhuang H, Khan J, et al: Role
of positron emission tomography with fluorine-18-deoxyglucose in
the detection of local recurrent and distant metastatic sarcoma.
Clin Nucl Med. 28:815–820. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Klaeser B, Mueller MD, Schmid RA, Guevara
C, Krause T and Wiskirchen J: PET-CT-guided interventions in the
management of FDG-positive lesions in patients suffering from solid
malignancies: initial experiences. Eur Radiol. 19:1780–1785. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Im HJ, Kim TS, Park SY, et al: Prediction
of tumour necrosis fractions using metabolic and volumetric 18F-FDG
PET/CT indices, after one course and at the completion of
neoadjuvant chemotherapy, in children and young adults with
osteosarcoma. Eur J Nucl Med Mol Imaging. 39:39–49. 2012.
View Article : Google Scholar
|
|
31
|
Bajpai J, Gamnagatti S, Kumar R, et al:
Role of MR imaging in osteosarcoma for evaluation and prediction of
chemotherapy response: correlation with histological necrosis.
Pediatr Radiol. 41:441–450. 2011. View Article : Google Scholar
|
|
32
|
Söderlund V, Larsson SA, Bauer HC, et al:
Use of 99mTc-MIBI scintigraphy in the evaluation of the response of
osteosarcoma to chemotherapy. Eur J Nucl Med. 24:511–515. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bajpai J, Kumar R, Sreenivas V, et al:
Prediction of chemotherapy response by PET-CT in osteosarcoma:
correlation with histologic necrosis. J Pediatr Hematol Oncol.
33:e271–e278. 2011.PubMed/NCBI
|
|
34
|
Hawkins DS, Rajendran JG, Conrad EU III,
Bruckner JD and Eary JF: Evaluation of chemotherapy response in
pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron
emission tomography. Cancer. 94:3277–3284. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sato J, Yanagawa T, Dobashi Y, Yamaji T,
Takagishi K and Watanabe H: Prognostic significance of 18 F-FDG
uptake in primary osteosarcoma after but not before chemotherapy: a
possible association with autocrine motility factor/phospho-glucose
isomerase expression. Clin Exp Metastasis. 25:427–435. 2008.
View Article : Google Scholar
|
|
36
|
Walter F, Federman N, Apichairuk W, et al:
18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in
pediatric patients. Pediatr Hematol Oncol. 28:579–587. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Costelloe CM, Raymond AK, Fitzgerald NE,
Mawlawi OR, Nunez RF, et al: Tumor necrosis in osteosarcoma:
inclusion of the point of greatest metabolic activity from F-18 FDG
PET/CT in the histopathologic analysis. Skeletal Radiol.
39:131–140. 2010. View Article : Google Scholar
|
|
38
|
Fischer BM, Mortensen J, Langer SW, Loft
A, Berthelsen AK, Petersen BI, et al: A prospective study of PET/CT
in initial staging of small-cell lung cancer: comparison with CT,
bone scintigraphy and bone marrow analysis. Ann Oncol. 18:338–345.
2007. View Article : Google Scholar
|
|
39
|
Kut V, Spies W, Spies S, Gooding W and
Argiris A: Staging and monitoring of small cell lung cancer using
[18F]fluoro-2-deoxy-D-glucose-positron emission tomography
(FDG-PET). Am J Clin Oncol. 30:45–50. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Erlemann R: MRI is highly sensitive for
the detection of bone marrow abnormalities, cortical destruction or
soft tissue tumors adjacent or infiltrating neighboring bones. Eur
J Radiol. 58:48–67. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Antoch G, Kanja J, Bauer S, Kuehl H,
Renzing-Koehler K, et al: Comparison of PET, CT, and dual-modality
PET/CT imaging for monitoring of imatinib (STI571) therapy in
patients with gastrointestinal stromal tumors. J Nucl Med.
45:357–365. 2004.PubMed/NCBI
|
|
42
|
Barker JM and Silvestri GA: Lung cancer
staging. Curr Opin Pulm Med. 8:287–293. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gupta NC, Graeber GM and Bishop HA:
Comparative efficacy of positron emission tomography with
fluorodeoxyglucose in evaluation of small (<1 cm), intermediate
(1 to 3 cm), and large (>3 cm) lymph node lesions. Chest.
117:773–778. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yi CA, Lee KS, Kim BT, et al: Tissue
characterization of solitary pulmonary nodule: comparative study
between helical dynamic CT and integrated PET/CT. J Nucl Med.
47:443–450. 2006.PubMed/NCBI
|
|
45
|
Tateishi U, Yamaguchi U, Seki K, et al:
Bone and soft-tissue sarcoma: preoperative staging with fluorine 18
fluorodeoxyglucose PET/CT and conventional imaging. Radiology.
245:839–847. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Huang TL, Liu RS, Chen TH, et al:
Comparison between F-18-FDG positron emission tomography and
histology for the assessment of tumor necrosis rates in primary
osteosarcoma. J Chin Med Assoc. 69:372–376. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kim JW, Kim HC, Park JW, et al: Predictive
value of (18)FDG PET-CT for tumour response in patients with
locally advanced rectal cancer treated by preoperative
chemoradiotherapy. Int J Colorectal Dis. 28:1217–1224. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Saifuddin A: The accuracy of imaging in
the local staging of appendicular osteosarcoma. Skeletal Radiol.
31:191–201. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Drzezga A, Souvatzoglou M, Eiber M, et al:
First clinical experience with integrated whole-body PET/MR:
comparison to PET/CT in patients with oncologic diagnoses. J Nucl
Med. 53:845–855. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Buchbender C, Heusner TA, Lauenstein TC,
Bockisch A and Antoch G: Oncologic PET/MRI, part 1: tumors of the
brain, head and neck, chest, abdomen, and pelvis. J Nucl Med.
53:928–938. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cheon GJ, Kim MS, Lee JA, Lee SY, Cho WH,
et al: Prediction model of chemotherapy response in osteosarcoma by
18F-FDG PET and MRI. J Nucl Med. 50:1435–1440. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Strobel K, Exner UE, Stumpe KD, et al: The
additional value of CT images interpretation in the differential
diagnosis of benign vs. malignant primary bone lesions with
18F-FDG-PET/CT. Eur J Nucl Med Mol Imaging. 35:2000–2008. 2008.
View Article : Google Scholar : PubMed/NCBI
|
